A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Study Number

4594825

Phase

Age Group

Adult

Principal Investigator

Purpose

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

Check your eligibility for this trial

Check now

Full Title

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central
Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients (CA0821215)

ClinicalTrials.Gov ID

NCT07015242

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.